Compare Agilent Technologies Inc (A) vs SpaceX (SPCX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs SpaceX — how do they compare? Agilent Technologies Inc trades at $128.6 (market cap $37.04B), while SpaceX trades at $145.68 (market cap $1.97T). The key difference: SpaceX is far larger — about 53.2× Agilent Technologies Inc's market cap, and Agilent Technologies Inc pays a 0.78% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| A | SPCX | |
|---|---|---|
Market Cap | $37.04B | $1.97T |
Sector | Health | Technology |
52-Week High | $157.20 | $202.09 |
52-Week Low | $110.24 | $135.00 |
Enterprise Value | $38.59B | $1.98T |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
SPCX trades at $160.42, down 0.86% amid its Nasdaq-100 debut. Technical indicators are neutral, with support at $154 and resistance at $167. The company reported 2025 revenue of $18.67B but a net loss of $4.94B, with negative profit margins and high valuation multiples like P/S of 108.68. Recent news highlights inclusion in the Nasdaq-100 and analyst optimism, though earnings misses and cash burn from heavy investing raise concerns.
Outlook: Strong analyst consensus (100% buy, $240.80 target) reflects long-term growth faith in SpaceX's space economy role. However, persistent losses, high valuations, and execution risks in capital-intensive projects present significant downside. Investors face volatility from earnings uncertainty and competitive pressures, balancing speculative growth potential against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
